Our top pick for
Surgalign Holdings Inc is a medical devices business based in the US. Surgalign shares (SRGA) are listed on the NASDAQ and all prices are listed in US Dollars. Surgalign employs 197 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$0.97|
|52-week range||$0.89 - $3.27|
|50-day moving average||$1.26|
|200-day moving average||$1.43|
|Wall St. target price||$3.14|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.10|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-2.02%|
|1 month (2021-09-24)||-25.95%|
|3 months (2021-07-23)||-9.35%|
|6 months (2021-04-23)||-50.76%|
|1 year (2020-10-23)||-50.51%|
|2 years (2019-10-23)||-65.60%|
|3 years (2018-10-23)||4.64|
|5 years (2016-10-21)||3.11|
Valuing Surgalign stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Surgalign's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Surgalign's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.6 million.
The EBITDA is a measure of a Surgalign's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$102.2 million|
|Gross profit TTM||$61.2 million|
|Return on assets TTM||-12.63%|
|Return on equity TTM||-348.23%|
|Market capitalisation||$138.5 million|
TTM: trailing 12 months
There are currently 6.0 million Surgalign shares held short by investors – that's known as Surgalign's "short interest". This figure is 5.1% down from 6.3 million last month.
There are a few different ways that this level of interest in shorting Surgalign shares can be evaluated.
Surgalign's "short interest ratio" (SIR) is the quantity of Surgalign shares currently shorted divided by the average quantity of Surgalign shares traded daily (recently around 3.3 million). Surgalign's SIR currently stands at 1.8. In other words for every 100,000 Surgalign shares traded daily on the market, roughly 1800 shares are currently held short.
However Surgalign's short interest can also be evaluated against the total number of Surgalign shares, or, against the total number of tradable Surgalign shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Surgalign's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Surgalign shares in existence, roughly 40 shares are currently held short) or 0.0486% of the tradable shares (for every 100,000 tradable Surgalign shares, roughly 49 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Surgalign.
Find out more about how you can short Surgalign stock.
We're not expecting Surgalign to pay a dividend over the next 12 months.
Over the last 12 months, Surgalign's shares have ranged in value from as little as $0.89 up to $3.27. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Surgalign's is 2.2513. This would suggest that Surgalign's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Surgalign Holdings, Inc. , a medical technology company, develops, manufactures, distributes, and markets spine implants worldwide. It offers products for thoracolumbar procedures, including Streamline TL Spinal Fixation system, a system for degenerative and complex spine procedures; and Streamline MIS Spinal Fixation system, a range of implants and instruments used via a percutaneous or mini-open approach; and interbody fusion devices, as well as products for cervical procedures, such as CervAlign ACP system, a comprehensive anterior cervical plate system; Fortilink-C IBF system, a cervical interbody fusion device that utilizes TETRAfuse 3D technology; and Streamline OCT system, a range of implants used in the occipito-cervico-thoracic posterior spine. The company also provides motion preservation systems comprising Coflex Interlaminar Stabilization device for the treatment of moderate to severe lumbar spinal stenosis in conjunction with decompression; HPS 2. 0 Universal Fixation system, a pedicle screw system used for posterior stabilization of the thoracolumbar spine; SImmetry SI Joint Fusion system, a minimally invasive surgical implant system to decrease opioid use, pain, and disability. In addition, it develops Augmented Reality and Artificial Intelligence digital surgery platform to enable digital spine surgery. The company markets its products through independent spine and biomaterial distributors to hospitals, ambulatory surgery centers, and healthcare providers, as well as through direct sales force.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.